1月12日消息，近日，专攻原子力显微镜（AFM）探针研发的探真纳米科技（衢州）有限公司完成新一 轮股权融资，获得衢州绿石新材料股权投资合伙企业（有限合伙）与杭州德甫股权投资有限责任公司共 计超千万元的投资。 据悉，融资轮次为Pre-A/A轮，资金将重点优化探针的批量化制备工艺，提升产品稳定性和良率。此外 还将用于原子力显微镜（AFM）探针的全品类研发与新产线的布置。 据悉，探真纳米科技成立于2016年，位于浙江省衢州市，凭借其在微纳加工领域多年的技术与工艺积 累，通过基于干法刻蚀的创新微纳加工工艺，实现了从晶圆起步的探针开发，在探针的曲率半径、深宽 比和使用寿命等关键指标上已部分处于国际领先水平。今年年初，公司自主研发的AFM探针产品已实 现上市销售。 原子力显微镜（AFM）是纳米科技、材料科学，半导体工业以及生命科学等诸多领域不可或缺的高精 度检测仪器，在半导体制造中，AFM承担着"质量把关"的角色，通过纳米级别的探针对芯片进行精密 扫描，判断工艺是否达标。AFM探针作为原子力显微镜的核心消耗部件，使用频率高且复购属性强， 但长期以来依赖进口，价格高昂且供应受限，在科研和产业应用中逐渐成为成本与供应链风险的 ...

摘要 ： 安益谱成功完成近亿元B轮融资。本轮融资将重点用于提升核心质谱产品的性能与产能，深化其在多个领域的应用探索，并加 速市场渗透。公司的技术实力与市场前景获得了投资方的高度认可。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 安益谱 （ 苏州）医疗科技有限公司（以下简称"安益谱"） 完成 近亿元人民币B轮融资 ，本轮融资由博远资 本、华大松禾领投，老股东元生创投持续追加投资，海能技术投资亦在快速落实中。 | 融资日期 | 融资轮次 | 融资金额 | | 投资方 | 关联机构 | | --- | --- | --- | --- | --- | --- | | 2025-12-05 | B轮 | 约亿元 | 博远资本 领投 | | 博远资本 | | | | | 华大松禾 领投 | | - | | | | | 元生创投 | | 元生创投 | | | | | 海能技术 | | 海能技术 同 回 | 资本认可，共助国产质谱腾飞 对于本次投资，各方均表达了对安益谱技术实力与市场前景的坚定信心。 常州华大松禾基金团队 表示："安益谱在高端质 ...

Core Insights - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises [2][3] Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models [3] - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [3][4] Product Development - The company continues to innovate in traditional product lines while expanding new product lines, including customized models for various industries, maintaining a stable customized business ratio of over 20% [3][4] - New Zhi Bio has achieved significant technological breakthroughs in ultrasonic processing and freeze-drying, enabling the development of industrial-grade products [3] Strategic Expansion - The company is focusing on integrating capital to accelerate industrial consolidation, exemplified by the acquisition of a 55% stake in Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [4] - New Zhi Bio is shifting its strategic focus towards high-end instruments and global expansion, leveraging the increasing emphasis on independent control of scientific instruments at the national level [5][6] Market Positioning - The company has reached a critical stage in achieving independent control over life science instruments, with some products nearing or surpassing international advanced levels [6] - New Zhi Bio plans to establish a localized service network for its overseas markets, moving from reliance on foreign distributors to a direct service model [6] Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative small and medium-sized enterprises, fostering a development pattern that balances quantity and quality [7] - The listing has enhanced the company's brand influence, talent attraction, and shareholder structure, allowing it to compete effectively in the talent market [7] - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [7]